Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts

Interactive Cardiovascular and Thoracic Surgery

Volumn 10, Issue 3, 2010, Pages 371-376

  Gunaydin, Serdar ^a   McCusker, Kevin ^b   Sari, Tamer ^c   Onur, Mehmet Ali ^d   Zorlutuna, Yaman ^c  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c BAYINDIR HOSPITAL   (Turkey)

^d HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cardiopulmonary bypass; Coronary artery bypass grafting; Hyaluronic acid

Indexed keywords

ANESTHETIC AGENT; CD11B ANTIGEN; CD18 ANTIGEN; HEPARIN; HYALURONIC ACID; INTERLEUKIN 6; LIQUEMINE; PROTAMINE; PROTAMINE SULFATE; UNCLASSIFIED DRUG;

ANESTHESIA INDUCTION; ARTICLE; BIOCOMPATIBILITY; BLOOD SAMPLING; CARDIOVASCULAR RISK; CELL ADHESION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DESORPTION; DRUG COATING; EXTRACORPOREAL CIRCULATION; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEPARINIZATION; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; THROMBOCYTE ADHESION; THROMBOCYTE COUNT;

ANTICOAGULANTS; ANTIGENS, CD11B; ANTIGENS, CD18; BIOLOGICAL MARKERS; CARDIOPULMONARY BYPASS; COATED MATERIALS, BIOCOMPATIBLE; COMPLEMENT C3; CORONARY ARTERY BYPASS; HEPARIN; HUMANS; HYALURONIC ACID; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; PLATELET ADHESIVENESS; PLATELET COUNT; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77649277073     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1510/icvts.2009.220756     Document Type: Article

References (13)

1. Ovrum E, Tangen G, Oystese R, Ringdal MAL, Istad R. Comparison of two heparin coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations. J Thorac Cardiovasc Surg 2001;121:324-330.
2. Aldea GS, Soltow LO, Chandler WL, Triggs CM, Vocelka CR, Crockett GI, Shin YT, Curtis WE, Verrier ED. Limitation of thrombin generation, platelet activation and inflammation by elimination of cardiotomy suction in patients undergoing CABG treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002;123:742-755.
3. Videm V, Mollnes TE, Fosse E, Mohr B, Bergh K, Hagve TA, Aasen AO, Svennevig JL. Heparin coated cardiopulmonary bypass equipment: biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg 1999;117:794-802.
4. Ovrum E, Tangen G, Oystese R, Ringdal ML, Istad R. Heparin coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery. J Card Surg 2003;18:140-146.
5. Magnani A, Albanese A, Lamponi S, Barbucci R. Blood-Interaction performance of differently sulphated hyaluronic acids. Thrombosis Res 1996;81:383-395.
6. Repo H, Jansson SE, Leirisalo-Repo M. Flow cytometric determination of CD11b upregulation in vivo. J Immunol Methods 1993;164:193-202.
7. Tanaka M, Motomura T, Kawada M, Anzai T, Kasori Y, Shiroya T, Shimura K, Onishi M, Mochizuki A. Blood compatible aspects of poly(2-methoxyethylacrylate) relationship between protein adsorption and platelet adhesion on PMEA surface. Biomaterials 2000;21:1471-1481.
8. Gunaydin S, Farsak B, Kocakulak M, Sari T, Yorgancioglu C, Zorlutuna Y. Clinical performance and biocompatibility of poly(2-methoxyethylacrylate) coated extracorporeal circuits. Ann Thorac Surg 2002;74:819-824.
9. Gunaydin S. Clinical significance of coated extracorporeal circuits: a review of novel technologies. Perfusion 2004;9:S33-S41.
10. Gunaydin S. Emerging technologies in biocompatible surface modifying additives: quest for physiologic cardiopulmonary bypass. Curr Med Chem - Cardiovascular & Hematologic Agents 2004;2:187-196.
11. Gunaydin S, McCusker K, Vijay V. Clinical performance and biocompatibility of novel hyaluronan-based heparin-bonded extracorporeal circuits. J Extra Corpor Technol 2005;37:290-295.
12. Gunaydin S, Farsak B, McCusker K, Vijay V, Sari T, Onur MA, Gurpinar A, Zorlutuna Y. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization. J Cardiovasc Med (Hagerstown) 2009;10:135-142.
13. Brown KA, Lewis SM, Hill TA, Macey MG, McCarthey DA, Grant VA, Treacher DF. Leucodepletion and the interaction of polymorphonuclear cells with endothelium in systemic inflammatory response syndrome. Perfusion 2001;16 Suppl:75-83.